Your Health, We Care
The clinical study of momelotinib is mainly based on data from the Phase 3 MOMENTUM trial and the SIMPLIFY-1 trial. Momelotinib has significant therapeutic effects in the treatment of high-risk patients with myelofibrosis, especially those with anemia symptoms.
Momolotinib has obtained market authorization in multiple countries and regions, including the United States, Europe, and Laos. These authorizations signify the widespread recognition and potential application of Molotinib in the treatment of bone marrow fibrosis.
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
